Compare Equinor ASA (EQNR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Eli Lilly And Co — how do they compare? Equinor ASA trades at $35.73 (market cap $82.75B), while Eli Lilly And Co trades at $1,181.09 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 12.4× Equinor ASA's market cap, and Equinor ASA pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| EQNR | LLY | |
|---|---|---|
Market Cap | $82.75B | $1.03T |
Sector | Energy | Health |
52-Week High | $42.40 | $1.24K |
52-Week Low | $22.41 | $625.65 |
Enterprise Value | $94.51B | $1.07T |
Dividend Yield | 4.24% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $36.19, up 0.36% on the day, with a bullish technical signal from moving averages. Recent earnings show mixed results, with a Q1 2026 beat but a Q3 2025 miss. The company maintains a strong balance sheet with $21.24B in cash and a low EV/EBITDA of 2.39. Recent news highlights strategic investments in subsea projects and a share buy-back program, reinforcing growth commitments.
The outlook is cautiously optimistic, supported by low valuation metrics and strategic asset expansions. Key risks include volatile energy prices and declining net income margins. Analyst sentiment is mixed, with a 30.43% buy rating, suggesting potential upside but requiring monitoring of execution on production targets.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
